TNG.PA Transgene SA

Healthcare Biotechnology Euronext Paris
0.7480 EUR
Close of Nov 7, 2026
0.6700 1.39
Market cap
EUR 208M
P/E
-
P/B
1.91x
ROE
-57.4%
Dividend yield
-
Fundamental score
0.8/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is TNG.PA undervalued?

Graham number

The Graham number of Transgene SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Transgene SA fundamental analysis

2 of 11 checks passed

ROE 0/2

The stock's ROE indicates a negative return (-62.47%) on shareholders' equity, suggesting poor financial performance.

ROA 0/2

The stock's ROA (-49.44%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

PBV 0/2

The stock's elevated P/BV ratio (3.81x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

DER 2/2

The stock has a low debt to equity ratio (6%), which means it has a small amount of debt compared to the ownership it holds

Revenue Growth 0/2

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

Net Profit Growth 0/2

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

Assets Growth 0/2

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

Graham Number 1/1

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

Dividend Growth 0/2

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

Dividend 0/2

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

Buffet Intrinsic Value 0/1

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Transgene SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Transgene SA

Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical tr…

Full company profile